ESMO real world data and digital oncology · 2026
An individualized patient decision-making tool to improve decision making in non-small cell lung cancer: a mixed methods approach.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sebri V, Provenzano L, Monzani D, Trovo' F, Macocchi D, Fernandez-Pinto M, Dollis N, Sarris E, Szewczyk M, Watermann I, Yonah L, Grasso R, Dorangricchia P, Miskovic V, Dumitrascu A D, Prelaj A, Pravettoni G
Аннотация
BACKGROUND: Patients with non-small cell lung cancer (NSCLC) are asked to make decisions during their cancer journey, with a relevant impact on their quality of life, treatment adherence, and clinical outcomes. Improving shared decision-making can be complex, thereby damaging patient-doctor communication.
MATERIALS AND METHODS: We followed three developmental phases, conducting focus groups, semistructured interviews, thinking-out-loud sessions, and a questionnaire with patients and semistructured interviews with physicians. Interviews were audio-recorded, verbatim transcribed, thematically coded, and analyzed. Phase I consisted of an evaluation of decisional needs during medical consultations; phase II tested the comprehensibility and usability of the first, static individualized patient decision aid (PDA); and phase III beta-tested the feasibility of the second, dynamic PDA.
RESULTS: Patients with NSCLC and oncologists agreed on the need to develop a tailored PDA to promote shared decision-making. Over the three phases, findings highlight that PDA can be a helpful decision tool to (i) provide clear and appropriate information to promote patients' knowledge and awareness, improving emotion regulation; (ii) assess patients' preferences and values, considering also if there is information that a patient do not desire to receive (i.e. survivorship rates); (iii) have a trustworthy relationship with the physicians; and (iv) involve caregivers in the process of care efficiently.
CONCLUSION: An online PDA for patients with NSCLC is proved to be a helpful tool for shared decision making, supporting clinical practice, treatment adherence, and clinical outcomes. A clinical trial will be started with newly diagnosed patients with NSCLC and their oncologists, involving the latest, dynamic version of PDA.
MATERIALS AND METHODS: We followed three developmental phases, conducting focus groups, semistructured interviews, thinking-out-loud sessions, and a questionnaire with patients and semistructured interviews with physicians. Interviews were audio-recorded, verbatim transcribed, thematically coded, and analyzed. Phase I consisted of an evaluation of decisional needs during medical consultations; phase II tested the comprehensibility and usability of the first, static individualized patient decision aid (PDA); and phase III beta-tested the feasibility of the second, dynamic PDA.
RESULTS: Patients with NSCLC and oncologists agreed on the need to develop a tailored PDA to promote shared decision-making. Over the three phases, findings highlight that PDA can be a helpful decision tool to (i) provide clear and appropriate information to promote patients' knowledge and awareness, improving emotion regulation; (ii) assess patients' preferences and values, considering also if there is information that a patient do not desire to receive (i.e. survivorship rates); (iii) have a trustworthy relationship with the physicians; and (iv) involve caregivers in the process of care efficiently.
CONCLUSION: An online PDA for patients with NSCLC is proved to be a helpful tool for shared decision making, supporting clinical practice, treatment adherence, and clinical outcomes. A clinical trial will be started with newly diagnosed patients with NSCLC and their oncologists, involving the latest, dynamic version of PDA.